The product was never submitted for approval by the FDA and is an unapproved drug for which safety and efficacy have not been ...
T he US Food and Drug Administration approved the first nasal spray epinephrine drug for severe allergic reactions known as ...
Additive effects with other products containing local anesthetics. Epinephrine: concomitant ergot-type oxytocic drugs not recommended; severe persistent hypertension may occur. Concomitant MAOIs ...
Lidocaine HCl 5mg/mL with epinephrine 1:200000 ... Concurrent vasopressor and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
Epinephrine is another word for adrenaline ... Other side effects of this drug may include difficulty breathing, ...
Epinephrine is under clinical development by Aquestive Therapeutics and currently in Phase I for Anaphylaxis. According to GlobalData, Phase I drugs for Anaphylaxis have an 89% phase transition ...